Imugene Past Earnings Performance
Past criteria checks 0/6
Imugene's earnings have been declining at an average annual rate of -47.1%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 30.2% per year.
Key information
-47.1%
Earnings growth rate
-35.5%
EPS growth rate
Biotechs Industry Growth | 9.6% |
Revenue growth rate | 30.2% |
Return on equity | -45.8% |
Net Margin | -593.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Sep 19We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate
May 30Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans
Jan 30Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More
Nov 11Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans
Aug 22Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Feb 28A Look At Imugene's (ASX:IMU) CEO Remuneration
Feb 17Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years
Dec 24Revenue & Expenses BreakdownBeta
How Imugene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 15 | -89 | 46 | 63 |
30 Sep 23 | 13 | -64 | 33 | 47 |
30 Jun 23 | 12 | -38 | 20 | 31 |
31 Mar 23 | 12 | -39 | 19 | 33 |
31 Dec 22 | 12 | -40 | 17 | 35 |
30 Sep 22 | 13 | -39 | 15 | 36 |
30 Jun 22 | 13 | -38 | 14 | 37 |
31 Mar 22 | 11 | -33 | 14 | 29 |
31 Dec 21 | 8 | -27 | 14 | 22 |
30 Sep 21 | 8 | -23 | 12 | 19 |
30 Jun 21 | 7 | -18 | 10 | 15 |
31 Mar 21 | 7 | -15 | 8 | 14 |
31 Dec 20 | 6 | -12 | 6 | 12 |
30 Sep 20 | 5 | -11 | 6 | 11 |
30 Jun 20 | 4 | -11 | 6 | 9 |
31 Mar 20 | 5 | -10 | 6 | 9 |
31 Dec 19 | 5 | -9 | 6 | 9 |
30 Sep 19 | 5 | -8 | 5 | 8 |
30 Jun 19 | 4 | -8 | 5 | 8 |
31 Mar 19 | 3 | -7 | 4 | 6 |
31 Dec 18 | 3 | -6 | 4 | 5 |
30 Sep 18 | 2 | -5 | 3 | 4 |
30 Jun 18 | 2 | -4 | 3 | 3 |
31 Mar 18 | 1 | -3 | 2 | 3 |
31 Dec 17 | 1 | -3 | 1 | 3 |
30 Sep 17 | 1 | -3 | 1 | 2 |
30 Jun 17 | 1 | -3 | 1 | 2 |
31 Mar 17 | 1 | -3 | 1 | 3 |
31 Dec 16 | 2 | -3 | 2 | 3 |
30 Sep 16 | 2 | -3 | 2 | 3 |
30 Jun 16 | 2 | -3 | 2 | 3 |
31 Mar 16 | 1 | -3 | 1 | 2 |
31 Dec 15 | 1 | -2 | 1 | 2 |
30 Sep 15 | 1 | -2 | 1 | 2 |
30 Jun 15 | 1 | -2 | 1 | 2 |
31 Mar 15 | 1 | -2 | 1 | 1 |
31 Dec 14 | 1 | -2 | 1 | 1 |
30 Sep 14 | 1 | -2 | 1 | 1 |
30 Jun 14 | 1 | -2 | 1 | 0 |
31 Mar 14 | 0 | -2 | 1 | 0 |
31 Dec 13 | 0 | -2 | 1 | 0 |
30 Sep 13 | 0 | -2 | 1 | 0 |
30 Jun 13 | 0 | -2 | 1 | 1 |
Quality Earnings: IMU is currently unprofitable.
Growing Profit Margin: IMU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMU is unprofitable, and losses have increased over the past 5 years at a rate of 47.1% per year.
Accelerating Growth: Unable to compare IMU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.6%).
Return on Equity
High ROE: IMU has a negative Return on Equity (-45.8%), as it is currently unprofitable.